THCT — Thc Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $0.02m
- $0.75m
Annual income statement for Thc Therapeutics, fiscal year end - July 31st, USD millions except per share, conversion factor applied.
2019 July 31st | R2020 July 31st | 2021 July 31st | 2022 July 31st | 2023 July 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 19.1 | 1.56 | 0.94 | 1.75 | 0.492 |
| Operating Profit | -19.1 | -1.56 | -0.94 | -1.75 | -0.492 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -23.3 | -1.93 | -1.89 | -1.52 | -0.387 |
| Net Income After Taxes | -23.3 | -1.93 | -1.89 | -1.52 | -0.387 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -23.3 | -1.93 | -1.89 | -1.52 | -0.387 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -23.3 | -1.93 | -1.89 | -1.52 | -0.387 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.13 | -0.107 | -0.08 | -0.046 | -0.012 |